ReviewTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2015
New approaches for cancer immunotherapy.
Review in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- Cancer research in Lebanon: Scope of the most recent publications of an academic institution (Review).Oncology letters · 2024Review
- Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics.Genes & diseases · 2023Review
- Cancer immunotherapy: A comprehensive appraisal of its modes of application.Oncology letters · 2021Review
- Review
- Review
- Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope.Frontiers in pharmacology · 2021Review
- Curcumin as an Adjuvant to Cancer Immunotherapy.Frontiers in oncology · 2021Review
- Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy.Journal of experimental & clinical cancer research : CR · 2020Review
- Review
- PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation.Virchows Archiv : an international journal of pathology · 2020Article
- Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates.Journal of oncology · 2019Review
- Recent advances in understanding immune phenotypes of thyroid carcinomas: prognostication and emerging therapies.F1000Research · 2019Review
- Monoclonal antibodies in cancer immunotherapy.Molecular biology reports · 2018Review
- Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma.Clinical drug investigation · 2018Review
- Cancer Immunotherapy, Part 3: Challenges and Future Trends.P & T : a peer-reviewed journal for formulary management · 2017Article
- Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations.P & T : a peer-reviewed journal for formulary management · 2017Article
- Cancer Immunotherapy, Part 1: Current Strategies and Agents.P & T : a peer-reviewed journal for formulary management · 2017Article
- A generic RNA pulsed DC based approach for developing therapeutic intervention against nasopharyngeal carcinoma.Human vaccines & immunotherapeutics · 2017Article
- Testis expressed 19 is a novel cancer-testis antigen expressed in bladder cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas.American journal of cancer research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy is a promising field that offers alternative methods for treatment of cancer. The current strategy consists of cancer vaccines, monoclonal antibodies, and cellular therapies. Cancer vaccines aim to eradicate cancer cells via immune system. Thus, they may attack these cells derived from any type of cancer, besides their role in preventing cancer. Lymphocytes and dendritic cells are often used in cellular therapy. In addition, monoclonal antibodies are designed to target specific antigens found in cancer cells. Currently, at least 12 clinically approved monoclonal antibodies are being used and many cancer vaccines are being developed with ongoing phase studies for cancer therapy. Relevant studies are focused on glioma and several other cancer types. Correspondingly, the combination of effective methods may enhance the efficacy of immunotherapy. It is thought that particularly immune checkpoint inhibitors will play a crucial role in immunotherapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.